ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia : Episode 7

Opinion

Video

January 26, 2024

Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.

EP: 1.Current Front-Line Treatment Options for CLL in 2023

EP: 2.Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA

EP: 3.Strategies for Managing Treatment-Naïve CLL with High-Risk Features

EP: 4.Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

EP: 5.Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL

EP: 6.Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy

EP: 7.Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

EP: 8.Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

EP: 9.Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

EP: 10.Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

EP: 11.Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

EP: 12.Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

EP: 13.Expert Insights into Investigation Therapies for CLL

EP: 14.Future Perspectives on the Treatment Landscape for CLL

Related Videos

Mansi R. Shah, MD

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.

Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute

Rena Callahan, MD, and Chandler Park, MD, FACP

John M. Burke, MD

Andrew Kuykendall, MD

Prithviraj Bose, MD, and Chandler Park, MD, FACP

Related Content

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine

December 10th 2024

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

The OncFive: Top Oncology Articles for the Week of 12/18

December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/8

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center

October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Chronic Lymphocytic Leukemia | © LAZLO- stock.adobe.com

December 10th 2024

First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

December 10th 2024

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

Related Content

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine

December 10th 2024

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

The OncFive: Top Oncology Articles for the Week of 12/18

December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/8

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center

October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Chronic Lymphocytic Leukemia | © LAZLO- stock.adobe.com

December 10th 2024

First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

December 10th 2024

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

Latest Conference Coverage

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.